Topical pranoprofen 0.1% reduces the ocular signs and symptoms of dry eyes and decreases inflammatory markers of conjunctival epithelial cells, according to a study in the latest journal of 

, Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China, randomized 60 patients with dry eye into two groups.

Group 1 was administered topical pranoprofen 0.1% plus topical sodium hyaluronate 0.1%, while group 2 received sodium hyaluronate without pranoprofen. The outcome measures included ocular surface disease index (OSDI), tear film break-up time (TBUT), Schirmer I test results, ocular surface staining (OSS) results and conjunctival HLA-DR expression.

Group 1 demonstrated a significantly lower OSDI, OSS, and HLA-DR-positive cells, compared to group 2. However, TBUT was significantly longer in group 1 than group 2. On day 30 of the follow-up OSS differences between the group decreased in significance, but there were continued differences in OSDI, TBUT and HLA-DR expression between group 1 and 2.

On postoperative days 15 and 30 OSDI, TBUT and HLA-DR expression in group 1 demonstrated significant improvement, compared with results achieved in group 2. There were no significant effects in either group in the Schirmer test I values at days 15 and 30.

The abstract for this study can be found 

Articles

Cornea

Topical pranoprofen 0.1% reduces the ocular signs and symptoms of dry eyes and decreases inflammatory markers of conjunctival epithelial cells.